華陽新材(600281.SH):2021年度預虧3500萬元-5200萬元
格隆匯2月4日丨華陽新材(600281.SH)公佈2021年度業績預虧公吿,公司預計2021年度實現歸屬於上市公司股東的淨利潤為-3500萬元到-5200萬元。公司預計2021年度實現歸屬於上市公司股東扣除非經常性損益後的淨利潤為-2800萬元到-4100萬元。
業績預虧的主要原因:(一)報吿期,公司對可能存在減值跡象的資產進行減值測試,並根據測試結果計提了約4711萬元的資產減值準備。(二)2020年度公司收到省財政廳土地出讓金返還財政專項資金8166萬元,並計入當年損益。與上年同期相比,報吿期公司無此類收益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.